J. Goldman & Co’s PTC Therapeutics PTCT Stock Holding History

J. Goldman & Co’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-52,000	Closed	-$1.04M	–	419
2017 Q3	$1.04M	Buy	+52,000	New	+$1.02M	0.05%	237

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's PTCT Position: Q4 2025 in Review

J. Goldman & Co sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 7,816 shares — an estimated $480K sold.

J. Goldman & Co first reported a position in PTCT in Q1 2015 and held it in 8 quarters. The position peaked at $12.4M in Q1 2017. 351 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

J. Goldman & Co reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 7,816 PTC Therapeutics shares in Q4 2025, an estimated $480K.
J. Goldman & Co first reported a position in PTC Therapeutics in Q1 2015 and held it in 8 quarters.
J. Goldman & Co's PTC Therapeutics position peaked at $12.4M in Q1 2017.
351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.